BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 173
- Registration Number
- NCT01188278
Methotrexate - Inadequate Response Device Sub-Study
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Device: Abatacept combination product (ACP)
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT01173120
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Phase 2
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT01170962
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Liver Associates Of Texas, Houston, Texas, United States
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT01167244
- Locations
- 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4000
- Registration Number
- NCT01166620
Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT01165216
- Locations
- 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan
A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: INX-08189Drug: Placebo
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT01159808
Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)
Completed
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2010-07-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT01155427
Experimental Study to Validate the Modified Glucose Disposal Test
Phase 1
Completed
- Conditions
- Diabetes
- Interventions
- Procedure: Insulin, glucose and staple isotopes
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT01152372
- Locations
- 🇺🇸
Profil Institute For Clinical Research, Inc. (Picr), Chula Vista, California, United States
Japanese Phase 1 Study of BMS-844203 (CT322)
Phase 1
Withdrawn
- Conditions
- Neoplasms
- Interventions
- Drug: BMS-844203 (CT-322)
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01146171
- Locations
- 🇯🇵
Local Institution, Osaka-Sayama-Shi, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath